+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "P2X Purinoceptor"

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021 - Product Thumbnail Image

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

  • Report
  • November 2021
  • 70 Pages
  • Global
From
P2X Purinoceptor 3 Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Thumbnail Image

P2X Purinoceptor 3 Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • October 2024
  • 84 Pages
  • Global
From
P2X Purinoceptor 7 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

P2X Purinoceptor 7 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 45 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

P2X Purinoceptors are a class of proteins found in the central nervous system (CNS) that are involved in the regulation of neurotransmission. They are activated by the binding of ATP, a nucleotide that is released from neurons during synaptic transmission. P2X Purinoceptors are involved in a variety of physiological processes, including pain perception, learning and memory, and motor control. As such, they are an important target for the development of CNS drugs. The P2X Purinoceptor market is composed of a variety of pharmaceutical companies that are researching and developing drugs that target these receptors. These drugs are being developed for a range of indications, including pain, epilepsy, and neurodegenerative diseases. Companies in this market include AstraZeneca, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more